{
    "clinical_study": {
        "@rank": "77113", 
        "arm_group": [
            {
                "arm_group_label": "Tiotropium + Olodaterol (high dose)", 
                "arm_group_type": "Experimental", 
                "description": "Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT"
            }, 
            {
                "arm_group_label": "Tiotropium + Olodaterol (low dose)", 
                "arm_group_type": "Experimental", 
                "description": "Tiotropium and Olodaterol  fixed dose combination (FDC) solution for inhalation - RESPIMAT"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol\n      fixed-dose combination (2.5 \u00b5g/ 5 \u00b5g, 5 \u00b5g/ 5 \u00b5g) delivered by the RESPIMAT inhaler after 3\n      weeks once daily treatment in Japanese patients with COPD."
        }, 
        "brief_title": "A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Diagnosis of chronic obstructive pulmonary disease\n\n          2. Relatively stable airway obstruction with post FEV1=<30% of predicted normal and< 80%\n             predicted normal and post FEV1/FVC <70%\n\n          3. Male or female Japanese patients, 40 years of age or older\n\n          4. Smoking history of more than 10 pack  years\n\n        Exclusion criteria:\n\n          1. Significant disease other than COPD\n\n          2. Clinically relevant abnormal lab values\n\n          3. History of asthma\n\n          4. Diagnosis of thyrotoxicosis\n\n          5. Diagnosis of paroxysmal tachycardia\n\n          6. A marked baseline prolongation of QT/QTc interval\n\n          7. A history of additional risk factors for Torsade de Pointes (TdP)\n\n          8. History of myocardial infarction within 1 year of screening visit\n\n          9. Unstable or life-threatening cardiac arrhythmia\n\n         10. Hospitalization for heart failure within the past year\n\n         11. Known active tuberculosis\n\n         12. Malignancy for which patient has undergone resection, radiation therapy or\n             chemotherapy within last five years\n\n         13. History of life-threatening pulmonary obstruction\n\n         14. History of cystic fibrosis\n\n         15. Clinically evident bronchiectasis\n\n         16. History of significant alcohol or drug abuse\n\n         17. Thoracotomy with pulmonary resection\n\n         18. Oral \u00df-adrenergics\n\n         19. Oral corticosteroid medication at unstable doses\n\n         20. Regular use of daytime oxygen therapy for more than one hour per day\n\n         21. Pulmonary rehabilitation program in the six weeks prior to the screening visit\n\n         22. Investigational drug within one month or six half lives (whichever is greater) prior\n             to screening visit\n\n         23. Known hypersensitivity to \u00df-adrenergic drugs, anticholinergics, BAC, EDTA\n\n         24. Pregnant or nursing women\n\n         25. Women of childbearing potential not using a highly effective method of birth control\n\n         26. Patients who have previously been randomized in this study or are currently\n             participating in another study\n\n         27. Patients who are unable to comply with pulmonary medication restrictions\n\n         28. Patients with narrow-angle glaucoma or micturition disorder due to prostatic\n             hyperplasia etc\n\n         29. Patients being treated with medications that prolong the QT/QTc interval"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703845", 
            "org_study_id": "1237.24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tiotropium + Olodaterol (high dose)", 
                "description": "Tiotropium + Olodaterol solution for inhalation", 
                "intervention_name": "Tiotropium (high dose) + Olodaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tiotropium + Olodaterol (low dose)", 
                "description": "Tiotropium + Olodaterol solution for inhalation", 
                "intervention_name": "Tiotropium (low dose) + Olodaterol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tiotropium"
        }, 
        "lastchanged_date": "November 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toshima-ku, Tokyo", 
                    "country": "Japan"
                }, 
                "name": "1237.24.24001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Open-label, Parallel-group Trial to Assess Pharmacokinetics and Safety of Tiotropium + Olodaterol Fixed-dose Combination (2.5 \u00b5g/ 5 \u00b5g, 5 \u00b5g/ 5 \u00b5g) Delivered by the RESPIMAT Inhaler After 3 Weeks Once Daily Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum measured concentration in plasma at steady state (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "15 min pre-dose and 5, 10, 20, 40 min, 1, 2, 3, and 4 hours following drug administration on day 21"
            }, 
            {
                "measure": "Area under the concentration-time curve in plasma over the time interval t1 to t2 at steady state (AUCt1 t2,ss)", 
                "safety_issue": "No", 
                "time_frame": "15 min pre-dose and 5, 10, 20, 40 min, 1, 2, 3, and 4 hours following drug administration on day 21"
            }, 
            {
                "measure": "Area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point at steady state (AUC0-tz,ss)", 
                "safety_issue": "No", 
                "time_frame": "15 min pre-dose and 5, 10, 20, 40 min, 1, 2, 3, and 4 hours following drug administration on day 21"
            }, 
            {
                "measure": "Time from dosing to the maximum concentration in plasma at steady state (tmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "day 21"
            }, 
            {
                "measure": "Amount that is eliminated in urine from the time point t1 to time point t2 at steady state (Aet1-t2,ss)", 
                "safety_issue": "No", 
                "time_frame": "from 0 to 2 and 2 to 4 hours following drug administration on day 21"
            }, 
            {
                "measure": "Fraction eliminated in urine from the time point t1 to time point t2 at steady state (fet1-t2,ss)", 
                "safety_issue": "No", 
                "time_frame": "from 0 to 2 and 2 to 4 hours following drug administration on day 21"
            }, 
            {
                "measure": "Renal clearance from the time point t1 until the time point t2 at steady state (CLR,t1-t2,ss)", 
                "safety_issue": "No", 
                "time_frame": "from 0 to 2 and 2 to 4 hours following drug administration on day 21"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events (including assessment based on physical examination, vital signs, laboratory evaluations,  ECG)", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks post dose"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}